This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Pfizer

Status

Completed

Conditions

COVID-19

Influenza, Human

Treatments

Biological: Quadrivalent Influenza Vaccine

Biological: Comirnaty

Study type

Observational

Funder types

Industry

Identifiers

NCT05858450

C4591061

Details and patient eligibility

About

This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.

Enrollment

3,442,996 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Enrolled in Optum claims database as of 31 August 2022 (date bivalent authorized).
Has a Pfizer-BioNTech mRNA bivalent COVID-19 or influenza vaccine (any type) between 31 August 2022 and 30 January 2023 (earliest vaccine is index date).
Aged >=18 years on the index date
365 days of continuous enrolment prior to index date

Exclusion criteria

Patients with a second dose of any type of bivalent mRNA COVID-19 or flu vaccine, disenrolled or died within 14 days following the first dose.
Has prior COVID-19 diagnosis (U07.1, any setting, any position) within 90 days (per CDC guidance on length of time before receiving a vaccine) before and on index.
Has influenza vaccine between 01 August -30 August 2022 (before study period).
Has a COVID-19 or influenza diagnosis code in any setting within 14 days after index vaccination (excluded from all cohorts).